Brief: Genfit FY Revenue Up At EUR 80.1 Mln

Genfit SA

01/03/2022 06:16

March 1 (Reuters) - GENFIT SA  GNFT.PA :
    * GENFIT ANNOUNCED ON MONDAY SOLID REVENUES AND CASH
POSITION AS
OF DECEMBER 31, 2021
    * CASH AND CASH EQUIVALENTS TOTALED EUR 258.8 MILLION AS OF
DECEMBER 31, 2021, WHICH INCLUDES EUR 120 MILLION UPFRONT
PAYMENT AND EUR 28 MILLION EQUITY INVESTMENT PURSUANT TO
LICENSING AGREEMENT SIGNED IN DEC. 2021 WITH IPSEN
    * REVENUES FOR 2021 WERE EUR 80.06 MILLION COMPARED TO EUR
0.76
MILLION FOR 2020
    * RECENT RAPID EXPANSION OF HIGHLY CONTAGIOUS OMICRON STRAIN
OF
COVID HAS CREATED ADDITIONAL COMPLICATIONS IN ENROLLING PATIENTS
AND IN CLINICAL TRIAL OPERATIONS GENERALLY
    * CURRENTLY DOES NOT ANTICIPATE OMICRON IMPACT TO
SUBSTANTIALLY
CHANGE GUIDANCE RELATED TO AVAILABILITY OF ELATIVE TOP LINE
RESULTS
    * WAS ABLE TO MINIMIZE DISRUPTION TO ELATIVE PHASE 3
CLINICAL
TRIAL OF ELAFIBRANOR IN PBC, WHICH ENROLLED ITS FIRST PATIENT IN
SEPTEMBER 2020 
    * IS CURRENTLY ASSESSING THE EXTENT OF COVID-19 IMPACT ON
ENROLLMENT TIMELINES, WILL PROVIDE UPDATE DURING NEXT WEBCAST
SCHEDULED FOR APRIL 7, 2022

Source text for Eikon:  ID:nGNE5ng82s 
Further company coverage:  GNFT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))